ERBB2 and triple-negative breast carcinoma: The IMPRESS dataset (56) consists of 126 breast H&E WSIs from 62 female patients with HER2-positive breast cancer and 64 female patients with triple-negative breast cancer, all of whom underwent neoadjuvant chemotherapy followed by surgical excision.